Edition:
India

Japan Tobacco Top-Line Results Of Phase 3 Clinical Studies Of JTZ-951 In Anemic Patients With Chronic Kidney Disease In Japan


Friday, 12 Jul 2019 

July 12 (Reuters) - Japan Tobacco Inc <2914.T>::TOP-LINE RESULTS OF PHASE 3 CLINICAL STUDIES OF JTZ-951 IN ANEMIC PATIENTS WITH CHRONIC KIDNEY DISEASE IN JAPAN.RESULTS SHOW BOTH STUDIES MET PRIMARY ENDPOINTS.JT AND TORII <<<4551.T>>> WILL AIM TO SUBMIT MARKETING APPLICATION FOR JTZ-951 IN JAPAN BASED ON RESULTS OF THIS AND OTHER CLINICAL STUDIES. 

Company Quote

2483.0
1.0 +0.04%
11:30am IST